Paraprobiotics as immunopotentiating agents of myelopoiesis

GUTIÉRREZ, FLORENCIA; GRAMAJO-LÓPEZ, ANDRÉS; JIMENEZ ÁVALOS, ARMANDO; IVIR, MAXIMILIANO; VILLENA, JULIO; ALVAREZ, SUSANA; SALVA, SUSANA

Mar del Plata

Congreso; SAIC. SAI. SAFIS 2018; 2018

Sociedad Argentina de Inmunología

Myelosuppression is the major dose-limiting toxicity of systemic cancer chemotherapy. At present, hematological rescue techniques are applied to reduce the chemotherapy-induced neutropenia that includes new adverse effects. Probiotic acid lactic bacteria (BL) has shown to be promising safe agents to reduce myelosuppression. We demonstrated that the dietary supplementation with probiotic Lactobacillus rhamnosus CRL 1505 (Lr05) improved steady-state and emergency granulopoiesis, the respiratory innate immune response and the resistance against respiratory pathogens in immunosupressed hosts. While the viability of the BL is an important factor to achieve optimal protective effects, it is also possible to stimulate immunity using non-viable BL. The aim of this work is to study the ability of paraprobiotics (cell fractions) from Lr05 to minimize myelosuppressive effects derived from chemotherapy. Adult Swiss-mice were orally treated with paraprobiotis, peptidoglycan (PG group) and cellular wall (CW group), during 15 consecutive days (8µg/mice/day). On day 6, paraprobiotic-treated and untreated control mice received one intraperitoneal dose of cyclophosphamide (Cy) (150 mg/kg). Before Cy-injection, both PG and CW groups increased the peroxidase (Px) score in blood and bone marrow (BM) myeloid cells compared with control (p